Skip to content

REGENEREX PHARMA, INC.: 10-Q filed 2019-10-30

What REGENEREX PHARMA, INC. reported in its quarterly report filed 2019-10-30 (fiscal Q2 2019): 23 published measures, 59 facts as tagged in accession 0001472375-19-000059.

This filing

Form
10-Q (quarterly report)
Filed
2019-10-30
Fiscal period
fiscal Q2 2019
Accession
0001472375-19-000059 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-09-30251,256USD
At 2019-03-31105,623USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-09-30671,681USD
At 2019-03-31475,308USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-09-30-420,425USD
At 2019-03-31-369,685USD
At 2018-09-30-344,488USD
At 2018-03-31-321,106USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-09-301,053USD
At 2019-03-3188,546USD
At 2018-09-301,083USD
At 2018-03-311,728USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-18,470USD92
2019-04-01 to 2019-09-30-50,740USD183
2018-07-01 to 2018-09-30-4,809USD92
2018-04-01 to 2018-09-30-23,382USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-04-01 to 2019-09-30154,751USD183
2018-04-01 to 2018-09-301,124USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-04-01 to 2019-09-3067,258USD183
2018-04-01 to 2018-09-30479USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-09-30-1,324,501USD
At 2019-03-31-1,273,761USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-11,622USD92
2019-04-01 to 2019-09-30-42,744USD183
2018-07-01 to 2018-09-30-4,820USD92
2018-04-01 to 2018-09-30-23,389USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-09-30245,923USD
At 2019-03-3197,616USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-07-01 to 2019-09-30-6,762USD92
2019-04-01 to 2019-09-30-9,889USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-09-30534,425USD
At 2019-03-31405,308USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-09-30167,574USD
At 2019-03-3138,348USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2019-09-305,333USD
At 2019-03-318,007USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-07-01 to 2019-09-3011,622USD92
2019-04-01 to 2019-09-3042,744USD183
2018-07-01 to 2018-09-304,820USD92
2018-04-01 to 2018-09-3023,389USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-09-30127,112,660shares
At 2019-03-31127,112,660shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-09-30776,963USD
At 2019-03-31776,963USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-09-3014,667USD
At 2019-03-3114,778USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-04-01 to 2019-09-3050,740USD183
2018-04-01 to 2018-09-3023,382USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2019-09-3011,385USD92
2019-04-01 to 2019-09-3028,211USD183
2018-07-01 to 2018-09-304,820USD92
2018-04-01 to 2018-09-3023,389USD183

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-04-01 to 2019-09-302,674USD183
2018-04-01 to 2018-09-302,674USD183

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2019-04-01 to 2019-09-301,344USD183
2019-04-01 to 2019-06-301,344USD91
2018-04-01 to 2018-09-302,674USD183
2018-04-01 to 2018-06-302,674USD91

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-09-30-235,800USD183

Inspect the source

Entity
REGENEREX PHARMA, INC. / CIK 0001357878
Captured
2026-09-21T17:18:44.819Z
SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))